1
|
Zamora-Ceballos M, Bárcena J, Mertens J. Eukaryotic CRFK Cells Motion Characterized with Atomic Force Microscopy. Int J Mol Sci 2022; 23:ijms232214369. [PMID: 36430849 PMCID: PMC9692694 DOI: 10.3390/ijms232214369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 11/16/2022] [Accepted: 11/17/2022] [Indexed: 11/22/2022] Open
Abstract
We performed a time-lapse imaging with atomic force microscopy (AFM) of the motion of eukaryotic CRFK (Crandell-Rees Feline Kidney) cells adhered onto a glass surface and anchored to other cells in culture medium at 37 °C. The main finding is a gradient in the spring constant of the actomyosin cortex along the cells axis. The rigidity increases at the rear of the cells during motion. This observation as well as a dramatic decrease of the volume suggests that cells may organize a dissymmetry in the skeleton network to expulse water and drive actively the rear edge.
Collapse
Affiliation(s)
- María Zamora-Ceballos
- Centro de Investigación en Sanidad Animal (CISA-INIA/CSIC), Valdeolmos, 28130 Madrid, Spain
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (CISA-INIA/CSIC), Valdeolmos, 28130 Madrid, Spain
| | - Johann Mertens
- Madrid Institute for Advanced Studies in Nanoscience (IMDEA Nanoscience), Campus de Cantoblanco, 28049 Madrid, Spain
- Correspondence:
| |
Collapse
|
2
|
Pacheco H, Lopes AM, Bárcena J, Blanco E, Abrantes J, Esteves P, Choquet R, Alves PC, Santos N. Multi‐event capture‐recapture models estimate the diagnostic performance of serological tests for myxoma and rabbit haemorrhagic disease viruses in the absence of reference samples. Transbound Emerg Dis 2022; 69:e3024-e3035. [DOI: 10.1111/tbed.14657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Revised: 07/07/2022] [Accepted: 07/07/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Henrique Pacheco
- CIISA – Centro de Investigação Interdisciplinar em Sanidade Animal Faculty of Veterinary Medicine University of Lisbon Lisbon Portugal
- CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos InBIO Laboratório Associado Universidade do Porto Vairão Portugal
- BIOPOLIS Program in Genomics Biodiversity and Land Planning CIBIO Vairão Portugal
| | - Ana M. Lopes
- CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos InBIO Laboratório Associado Universidade do Porto Vairão Portugal
- BIOPOLIS Program in Genomics Biodiversity and Land Planning CIBIO Vairão Portugal
- Instituto de Ciências Biomédicas Abel Salazar (ICBAS)/Unidade Multidisciplinar de Investigação Biomédica (UMIB) University of Porto Porto Portugal
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (CISA‐INIA/CSIC) Valdeolmos Madrid Spain
| | - Esther Blanco
- Centro de Investigación en Sanidad Animal (CISA‐INIA/CSIC) Valdeolmos Madrid Spain
| | - Joana Abrantes
- CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos InBIO Laboratório Associado Universidade do Porto Vairão Portugal
- BIOPOLIS Program in Genomics Biodiversity and Land Planning CIBIO Vairão Portugal
- Department of Biology Faculty of Sciences University of Porto Porto Portugal
| | - Pedro Esteves
- CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos InBIO Laboratório Associado Universidade do Porto Vairão Portugal
- BIOPOLIS Program in Genomics Biodiversity and Land Planning CIBIO Vairão Portugal
- Department of Biology Faculty of Sciences University of Porto Porto Portugal
| | - Rémi Choquet
- CEFE – Centre d’Écologie Fonctionnelle et Évolutive Univ Montpellier CNRS EPHE, IRD Montpellier France
| | - Paulo Célio Alves
- CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos InBIO Laboratório Associado Universidade do Porto Vairão Portugal
- BIOPOLIS Program in Genomics Biodiversity and Land Planning CIBIO Vairão Portugal
- Department of Biology Faculty of Sciences University of Porto Porto Portugal
- Estação Biológica de Mértola (EBM) CIBIO Mértola Portugal
| | - Nuno Santos
- CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos InBIO Laboratório Associado Universidade do Porto Vairão Portugal
- BIOPOLIS Program in Genomics Biodiversity and Land Planning CIBIO Vairão Portugal
- Estação Biológica de Mértola (EBM) CIBIO Mértola Portugal
| |
Collapse
|
3
|
Zamora-Ceballos M, Moreno N, Gil-Cantero D, Castón JR, Blanco E, Bárcena J. Immunogenicity of Multi-Target Chimeric RHDV Virus-like Particles Delivering Foreign B-Cell Epitopes. Vaccines (Basel) 2022; 10:vaccines10020229. [PMID: 35214688 PMCID: PMC8875457 DOI: 10.3390/vaccines10020229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 01/29/2022] [Accepted: 01/31/2022] [Indexed: 11/16/2022] Open
Abstract
The rabbit hemorrhagic disease virus (RHDV) vaccine platform is a nanoparticle composed of 180 copies of the viral capsid protein, VP60, self-assembled into virus-like particles (VLPs). RHDV VLPs are able to accept the simultaneous incorporation of target epitopes at different insertion sites. The resulting chimeric RHDV VLPs displaying immunogenic foreign antigens have been shown to induce specific protective immune responses against inserted heterologous T-cytotoxic and B-cell epitopes in the mouse and pig models. In this study, we explored whether RHDV-based engineered VLPs can be developed as efficient multivalent vaccines co-delivering different foreign B-cell antigens. We generated bivalent chimeric RHDV VLPs displaying two model B-cell epitopes at different surface-exposed insertion sites, as well as the corresponding monovalent chimeric VLPs. The immunogenic potential of the bivalent chimeric VLPs versus the monovalent constructs was assessed in the mouse model. We found that the bivalent chimeric VLPs elicited a strong and balanced antibody response towards the two target epitopes tested, although slight reductions were observed in the levels of specific serum antibody titers induced by bivalent chimeric VLPs as compared with the corresponding monovalent constructs. These results suggest that RHDV VLPs could represent a promising platform for the development of efficient multivalent vaccines.
Collapse
Affiliation(s)
- María Zamora-Ceballos
- Instituto Centro de Investigación en Sanidad Animal (CISA-INIA/CSIC), Valdeolmos, 28130 Madrid, Spain; (M.Z.-C.); (N.M.); (E.B.)
| | - Noelia Moreno
- Instituto Centro de Investigación en Sanidad Animal (CISA-INIA/CSIC), Valdeolmos, 28130 Madrid, Spain; (M.Z.-C.); (N.M.); (E.B.)
| | - David Gil-Cantero
- Department of Structure of Macromolecules, Centro Nacional de Biotecnología/CSIC, Cantoblanco, 28049 Madrid, Spain; (D.G.-C.); (J.R.C.)
| | - José R. Castón
- Department of Structure of Macromolecules, Centro Nacional de Biotecnología/CSIC, Cantoblanco, 28049 Madrid, Spain; (D.G.-C.); (J.R.C.)
| | - Esther Blanco
- Instituto Centro de Investigación en Sanidad Animal (CISA-INIA/CSIC), Valdeolmos, 28130 Madrid, Spain; (M.Z.-C.); (N.M.); (E.B.)
| | - Juan Bárcena
- Instituto Centro de Investigación en Sanidad Animal (CISA-INIA/CSIC), Valdeolmos, 28130 Madrid, Spain; (M.Z.-C.); (N.M.); (E.B.)
- Correspondence: ; Tel.: +34-916-202-300
| |
Collapse
|
4
|
Rangel G, Martín V, Bárcena J, Blanco E, Alejo A. An Adenovirus Vector Expressing FMDV RNA Polymerase Combined with a Chimeric VLP Harboring a Neutralizing Epitope as a Prime Boost Strategy to Induce FMDV-Specific Humoral and Cellular Responses. Pharmaceuticals (Basel) 2021; 14:ph14070675. [PMID: 34358101 PMCID: PMC8308840 DOI: 10.3390/ph14070675] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Revised: 07/06/2021] [Accepted: 07/12/2021] [Indexed: 11/16/2022] Open
Abstract
Foot and mouth disease is a highly contagious disease affecting cattle, sheep, and swine among other cloven-hoofed animals that imposes serious economic burden by its direct effects on farm productivity as well as on commerce of farmed produce. Vaccination using inactivated viral strains of the different serotypes is an effective protective measure, but has several drawbacks including a lack of cross protection and the perils associated with the large-scale growth of infectious virus. We have previously developed chimeric virus-like particles (VLPs) bearing an FMDV epitope which induced strong specific humoral responses in vaccinated pigs but conferred only partial protection against homologous challenge. While this and other FMD vaccines under development mostly rely on the induction of neutralizing responses, it is thought that induction of specific T-cell responses might improve both cross protective efficacy as well as duration of immunity. Therefore, we here describe the development of a recombinant adenovirus expressing the highly conserved nonstructural FMDV 3D protein as well as its capacity to induce specific T-cell responses in a murine model. We further describe the generation of an FMDV serotype C-specific chimeric VLP and analyze the immunogenicity of two different prime-boost strategies combining both elements in mice. This combination can effectively induce both humoral and cellular FMDV-specific responses eliciting high titers of ELISA and neutralizing antibodies anti-FMDV as well as a high frequency of IFNγ-secreting cells. These results provide the basis for further testing of this anti FMD vaccination strategy in cattle or pig, two of the most relevant natural host of this pathogen.
Collapse
Affiliation(s)
- Giselle Rangel
- Centro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain; (G.R.); (V.M.); (J.B.); (E.B.)
- Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICA-SAT-AIP), City of Knowledge, Panama 0843-01103, Panama
| | - Verónica Martín
- Centro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain; (G.R.); (V.M.); (J.B.); (E.B.)
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain; (G.R.); (V.M.); (J.B.); (E.B.)
| | - Esther Blanco
- Centro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain; (G.R.); (V.M.); (J.B.); (E.B.)
| | - Alí Alejo
- Centro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain; (G.R.); (V.M.); (J.B.); (E.B.)
- Correspondence: ; Tel.: +34-91-6202300
| |
Collapse
|
5
|
Rangel G, Bárcena J, Moreno N, Mata CP, Castón JR, Alejo A, Blanco E. Chimeric RHDV Virus-Like Particles Displaying Foot-and-Mouth Disease Virus Epitopes Elicit Neutralizing Antibodies and Confer Partial Protection in Pigs. Vaccines (Basel) 2021; 9:vaccines9050470. [PMID: 34066934 PMCID: PMC8148555 DOI: 10.3390/vaccines9050470] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 04/29/2021] [Accepted: 05/03/2021] [Indexed: 12/29/2022] Open
Abstract
Currently there is a clear trend towards the establishment of virus-like particles (VLPs) as a powerful tool for vaccine development. VLPs are tunable nanoparticles that can be engineered to be used as platforms for multimeric display of foreign antigens. We have previously reported that VLPs derived from rabbit hemorrhagic disease virus (RHDV) constitute an excellent vaccine vector, capable of inducing specific protective immune responses against inserted heterologous T-cytotoxic and B-cell epitopes. Here, we evaluate the ability of chimeric RHDV VLPs to elicit immune response and protection against Foot-and-Mouth disease virus (FMDV), one of the most devastating livestock diseases. For this purpose, we generated a set of chimeric VLPs containing two FMDV-derived epitopes: a neutralizing B-cell epitope (VP1 (140-158)) and a T-cell epitope [3A (21-35)]. The epitopes were inserted joined or individually at two different locations within the RHDV capsid protein. The immunogenicity and protection potential of the chimeric VLPs were analyzed in the mouse and pig models. Herein we show that the RHDV engineered VLPs displaying FMDV-derived epitopes elicit a robust neutralizing immune response in mice and pigs, affording partial clinical protection against an FMDV challenge in pigs.
Collapse
Affiliation(s)
- Giselle Rangel
- Centro de Investigación en Sanidad Animal (CISA, CSIC-INIA), Valdeolmos, 28130 Madrid, Spain; (G.R.); (J.B.); (N.M.); (A.A.)
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (CISA, CSIC-INIA), Valdeolmos, 28130 Madrid, Spain; (G.R.); (J.B.); (N.M.); (A.A.)
| | - Noelia Moreno
- Centro de Investigación en Sanidad Animal (CISA, CSIC-INIA), Valdeolmos, 28130 Madrid, Spain; (G.R.); (J.B.); (N.M.); (A.A.)
| | - Carlos P. Mata
- Department of Structure of Macromolecules, Centro Nacional de Biotecnología/CSIC, Cantoblanco, 28049 Madrid, Spain; (C.P.M.); (J.R.C.)
| | - José R. Castón
- Department of Structure of Macromolecules, Centro Nacional de Biotecnología/CSIC, Cantoblanco, 28049 Madrid, Spain; (C.P.M.); (J.R.C.)
| | - Alí Alejo
- Centro de Investigación en Sanidad Animal (CISA, CSIC-INIA), Valdeolmos, 28130 Madrid, Spain; (G.R.); (J.B.); (N.M.); (A.A.)
| | - Esther Blanco
- Centro de Investigación en Sanidad Animal (CISA, CSIC-INIA), Valdeolmos, 28130 Madrid, Spain; (G.R.); (J.B.); (N.M.); (A.A.)
- Correspondence: ; Tel.: +34-916-202-300
| |
Collapse
|
6
|
Cubillos-Zapata C, Angulo I, Almanza H, Borrego B, Zamora-Ceballos M, Castón JR, Mena I, Blanco E, Bárcena J. Precise location of linear epitopes on the capsid surface of feline calicivirus recognized by neutralizing and non-neutralizing monoclonal antibodies. Vet Res 2020; 51:59. [PMID: 32357948 PMCID: PMC7195702 DOI: 10.1186/s13567-020-00785-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Accepted: 04/21/2020] [Indexed: 12/16/2022] Open
Abstract
We report the generation, characterization and epitope mapping of a panel of 26 monoclonal antibodies (MAbs) against the VP1 capsid protein of feline calicivirus (FCV). Two close but distinct linear epitopes were identified at the capsid outermost surface (P2 subdomain) of VP1, within the E5′HVR antigenic hypervariable region: one spanning amino acids 431-435 (PAGDY), highly conserved and recognized by non-neutralizing MAbs; and a second epitope spanning amino acids 445-451 (ITTANQY), highly variable and recognized by neutralizing MAbs. These antibodies might be valuable for diagnostic applications, as well as for further research in different aspects of the biology of FCV.
Collapse
Affiliation(s)
- Carolina Cubillos-Zapata
- Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain.,Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz Hospital, 28046, Madrid, Spain
| | - Iván Angulo
- Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain
| | - Horacio Almanza
- Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain.,Facultad de Medicina y Psicología de la Universidad Autónoma de Baja California, Tijuana, Mexico
| | - Belén Borrego
- Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain
| | | | - José R Castón
- Department of Structure of Macromolecules, Centro Nacional de Biotecnología/CSIC, Cantoblanco, Madrid, Spain
| | - Ignacio Mena
- Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain.,Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
| | - Esther Blanco
- Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain.
| |
Collapse
|
7
|
Rouco C, Abrantes J, Serronha A, Lopes AM, Maio E, Magalhães MJ, Blanco E, Bárcena J, Esteves PJ, Santos N, Alves PC, Monterroso P. Epidemiology of RHDV2 (Lagovirus europaeus/GI.2) in free-living wild European rabbits in Portugal. Transbound Emerg Dis 2017; 65:e373-e382. [DOI: 10.1111/tbed.12767] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Indexed: 01/29/2023]
Affiliation(s)
- C. Rouco
- Departamento de Zoología; Facultad de Ciencias de la Universidad de Córdoba; Córdoba Spain
| | - J. Abrantes
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
| | - A. Serronha
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
| | - A. M. Lopes
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
- Instituto de Ciências Biomédicas Abel Salazar (ICBAS)/Unidade Multidisciplinar de Investigação Biomédica (UMIB); Universidade do Porto; Porto Portugal
| | - E. Maio
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
| | - M. J. Magalhães
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
| | - E. Blanco
- Centro de Investigación en Sanidad Animal (INIA-CISA); Valdeolmos Madrid Spain
| | - J. Bárcena
- Centro de Investigación en Sanidad Animal (INIA-CISA); Valdeolmos Madrid Spain
| | - P. J. Esteves
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
- Departamento de Biologia; Faculdade de Ciências da Universidade do Porto; Porto Portugal
| | - N. Santos
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
| | - P. C. Alves
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
- Departamento de Biologia; Faculdade de Ciências da Universidade do Porto; Porto Portugal
- Wildlife Biology Program; University of Montana; Missoula MT USA
| | - P. Monterroso
- CIBIO/InBio; Centro de Investigação em Biodiversidade e Recursos Genéticos; Universidade do Porto; Vairão Portugal
| |
Collapse
|
8
|
Le Pendu J, Abrantes J, Bertagnoli S, Guitton JS, Le Gall-Reculé G, Lopes AM, Marchandeau S, Alda F, Almeida T, Célio AP, Bárcena J, Burmakina G, Blanco E, Calvete C, Cavadini P, Cooke B, Dalton K, Delibes Mateos M, Deptula W, Eden JS, Wang F, Ferreira CC, Ferreira P, Foronda P, Gonçalves D, Gavier-Widén D, Hall R, Hukowska-Szematowicz B, Kerr P, Kovaliski J, Lavazza A, Mahar J, Malogolovkin A, Marques RM, Marques S, Martin-Alonso A, Monterroso P, Moreno S, Mutze G, Neimanis A, Niedzwiedzka-Rystwej P, Peacock D, Parra F, Rocchi M, Rouco C, Ruvoën-Clouet N, Silva E, Silvério D, Strive T, Thompson G, Tokarz-Deptula B, Esteves P. Proposal for a unified classification system and nomenclature of lagoviruses. J Gen Virol 2017; 98:1658-1666. [PMID: 28714849 DOI: 10.1099/jgv.0.000840] [Citation(s) in RCA: 118] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Lagoviruses belong to the Caliciviridae family. They were first recognized as highly pathogenic viruses of the European rabbit (Oryctolagus cuniculus) and European brown hare (Lepus europaeus) that emerged in the 1970-1980s, namely, rabbit haemorrhagic disease virus (RHDV) and European brown hare syndrome virus (EBHSV), according to the host species from which they had been first detected. However, the diversity of lagoviruses has recently expanded to include new related viruses with varying pathogenicity, geographic distribution and host ranges. Together with the frequent recombination observed amongst circulating viruses, there is a clear need to establish precise guidelines for classifying and naming lagovirus strains. Therefore, here we propose a new nomenclature based on phylogenetic relationships. In this new nomenclature, a single species of lagovirus would be recognized and called Lagovirus europaeus. The species would be divided into two genogroups that correspond to RHDV- and EBHSV-related viruses, respectively. Genogroups could be subdivided into genotypes, which could themselves be subdivided into phylogenetically well-supported variants. Based on available sequences, pairwise distance cutoffs have been defined, but with the accumulation of new sequences these cutoffs may need to be revised. We propose that an international working group could coordinate the nomenclature of lagoviruses and any proposals for revision.
Collapse
Affiliation(s)
- Jacques Le Pendu
- CRCINA, Inserm, Université d'Angers, Université de Nantes, Nantes, France
| | - Joana Abrantes
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal
| | | | - Jean-Sébastien Guitton
- Department of Studies and Research, National Hunting and Wildlife Agency (ONCFS), Nantes, France
| | - Ghislaine Le Gall-Reculé
- French Agency for Food, Environmental and Occupational Health & Safety (Anses), Ploufragan- Plouzané Laboratory, Avian and Rabbit Virology Immunology Parasitology Unit, Ploufragan, France
| | - Ana Margarida Lopes
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal
| | - Stéphane Marchandeau
- Department of Studies and Research, National Hunting and Wildlife Agency (ONCFS), Nantes, France
| | - Fernando Alda
- Louisiana State University, Museum of Natural Science, 119 Foster Hall, Baton Rouge, USA
| | - Tereza Almeida
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal.,Department of Studies and Research, National Hunting and Wildlife Agency (ONCFS), Nantes, France
| | - Alves Paulo Célio
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal.,Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal.,Wildlife Biology Program, University of Montana, 32 Campus Drive, Missoula, USA
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, 28130 Madrid, Spain
| | - Galina Burmakina
- National Research Institute of Veterinary Virology and Microbiology (VNIIVViM), Pokrov, Russia
| | - Esther Blanco
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, 28130 Madrid, Spain
| | - Carlos Calvete
- Animal Production and Health Department, Agrifood Research and Technology Centre of Aragon (CITA). Agrifood Institute of Aragon-IA2 (CITA-Zaragoza University), 50059 Zaragoza, Spain
| | - Patrizia Cavadini
- Proteomic and Virology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini" (IZSLER), Via Antonio Bianchi 7/9, 25124 Brescia, Italy
| | - Brian Cooke
- Invasive Animals Cooperative Research Centre and Institute of Applied Ecology, University of Canberra, Canberra, Australia
| | - Kevin Dalton
- Departamento de Bioquímica y Biología Molecular, Edificio Santiago Gascón, Instituto Universitario de Biotecnología de Asturias, Universidad de Oviedo, Asturias, Spain
| | - Miguel Delibes Mateos
- Departamento de Biología Vegetal y Ecología, Facultad de Biología, Universidad de Sevilla, Apartado 1095, 41080 Sevilla, Spain
| | - Wieslaw Deptula
- Department of Microbiology, University of Szczecin, Faculty of Biology, Felczaka 3c,50 71-412 Szczecin, Poland
| | - John Sebastian Eden
- Marie Bashir Institute for Infectious Diseases and Biosecurity, Charles Perkins Centre, School of Life and Environmental Sciences and Sydney Medical School, the University of Sydney, Sydney, Australia
| | - Fang Wang
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biologicals Engineering and Technology, Ministry of Agriculture, National Center for Engineering Research of Veterinary Bio-products, Nanjing, PR China
| | - Catarina C Ferreira
- Department of Biology, Trent University, Peterborough, Ontario, Canada.,Department of Conservation Biology, UFZ - Helmholtz Centre for Environmental Research, Leipzig, Germany
| | - Paula Ferreira
- Department of Anatomy, ICBAS (Abel Salazar Institute for Biomedical Science) and UMIB (Unit for Multidisciplinary Biomedical Research), University of Porto, Portugal
| | - Pilar Foronda
- Department Obstetrics & Gynecology, Pediatrics, Preventive Medicine & Public Health, Toxicology, Forensic Medicine and Parasitology, University Institute of Tropical Diseases and Public Health of the Canary Islands. Universidad de La Laguna, Canary Islands, Spain
| | - David Gonçalves
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal.,Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal
| | - Dolores Gavier-Widén
- Department of Pathology and Wildlife Diseases, National Veterinary Institute (SVA), Uppsala, Sweden.,Department of BiomedicalSciences and Veterinary Public Health, Swedish University of AgriculturalSciences, Uppsala, Sweden
| | - Robin Hall
- CSIRO Health & Biosecurity, Canberra, Australia
| | - Beata Hukowska-Szematowicz
- Department of Immunology, University of Szczecin, Faculty of Biology, Z. Felczaka 3c, 71- 412 Szczecin, Poland
| | - Peter Kerr
- Invasive Animals Cooperative Research Centre, University of Canberra, Bruce, Australia
| | - John Kovaliski
- Primary Industries and Regions SA, Adelaide, SA, Australia
| | - Antonio Lavazza
- Proteomic and Virology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini" (IZSLER), Via Antonio Bianchi 7/9, 25124 Brescia, Italy
| | - Jackie Mahar
- Marie Bashir Institute for Infectious Diseases and Biosecurity, Charles Perkins Centre, School of Life and Environmental Sciences and Sydney Medical School, the University of Sydney, Sydney, Australia.,Invasive Animals Cooperative Research Centre, University of Canberra, Bruce, Australia
| | - Alexander Malogolovkin
- National Research Institute of Veterinary Virology and Microbiology (VNIIVViM), Pokrov, Russia
| | - Raquel M Marques
- Department of Anatomy, ICBAS (Abel Salazar Institute for Biomedical Science) and UMIB (Unit for Multidisciplinary Biomedical Research), University of Porto, Portugal
| | - Sara Marques
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal.,Departamento Clínicas Veterinárias - ICBAS, Instituto de Ciências Biomédicas de Abe Salazar, Universidade do Porto, Porto, Portugal
| | - Aaron Martin-Alonso
- Department Obstetrics & Gynecology, Pediatrics, Preventive Medicine & Public Health, Toxicology, Forensic Medicine and Parasitology, University Institute of Tropical Diseases and Public Health of the Canary Islands. Universidad de La Laguna, Canary Islands, Spain
| | - Pedro Monterroso
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal
| | - Sacramento Moreno
- Ethology and Biodiversity Conservation Department, Doñana, Biological Station-CSIC, Américo Vespucio S/N, 41092 Seville, Spain
| | - Greg Mutze
- Primary Industries and Regions SA, Adelaide, SA, Australia
| | - Aleksija Neimanis
- Department of Pathology and Wildlife Diseases, National Veterinary Institute (SVA), Uppsala, Sweden.,Department of BiomedicalSciences and Veterinary Public Health, Swedish University of AgriculturalSciences, Uppsala, Sweden
| | | | - David Peacock
- Primary Industries and Regions SA, Adelaide, SA, Australia
| | - Francisco Parra
- Departamento de Bioquímica y Biología Molecular, Edificio Santiago Gascón, Instituto Universitario de Biotecnología de Asturias, Universidad de Oviedo, Asturias, Spain
| | - Mara Rocchi
- Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK
| | - Carlos Rouco
- Departamento de Zoología, Campus de Rabanales, Universidad de Córdoba, 14071 Córdoba, Spain
| | | | - Eliane Silva
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal.,Departamento Clínicas Veterinárias - ICBAS, Instituto de Ciências Biomédicas de Abe Salazar, Universidade do Porto, Porto, Portugal
| | - Diogo Silvério
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal
| | | | - Gertrudes Thompson
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal.,Departamento Clínicas Veterinárias - ICBAS, Instituto de Ciências Biomédicas de Abe Salazar, Universidade do Porto, Porto, Portugal
| | - Beata Tokarz-Deptula
- Department of Microbiology, University of Szczecin, Faculty of Biology, Felczaka 3c,50 71-412 Szczecin, Poland
| | - Pedro Esteves
- CIBIO/InBio, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Vairão, Portugal.,Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal.,Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde (CESPU), Gandra, Portugal
| |
Collapse
|
9
|
López-Vidal J, Gómez-Sebastián S, Bárcena J, Nuñez MDC, Martínez-Alonso D, Dudognon B, Guijarro E, Escribano JM. Improved Production Efficiency of Virus-Like Particles by the Baculovirus Expression Vector System. PLoS One 2015; 10:e0140039. [PMID: 26458221 PMCID: PMC4601761 DOI: 10.1371/journal.pone.0140039] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2015] [Accepted: 09/21/2015] [Indexed: 12/29/2022] Open
Abstract
Vaccines based on virus-like particles (VLPs) have proven effective in humans and animals. In this regard, the baculovirus expression vector system (BEVS) is one of the technologies of choice to generate such highly immunogenic vaccines. The extended use of these vaccines for human and animal populations is constrained because of high production costs, therefore a significant improvement in productivity is crucial to ensure their commercial viability. Here we describe the use of the previously described baculovirus expression cassette, called TB, to model the production of two VLP-forming vaccine antigens in insect cells. Capsid proteins from porcine circovirus type 2 (PCV2 Cap) and from the calicivirus that causes rabbit hemorrhagic disease (RHDV VP60) were expressed in insect cells using baculoviruses genetically engineered with the TB expression cassette. Productivity was compared to that obtained using standard counterpart vectors expressing the same proteins under the control of the polyhedrin promoter. Our results demonstrate that the use of the TB expression cassette increased the production yields of these vaccine antigens by around 300% with respect to the standard vectors. The recombinant proteins produced by TB-modified vectors were fully functional, forming VLPs identical in size and shape to those generated by the standard baculoviruses, as determined by electron microscopy analysis. The use of the TB expression cassette implies a simple modification of the baculovirus vectors that significantly improves the cost efficiency of VLP-based vaccine production, thereby facilitating the commercial viability and broad application of these vaccines for human and animal health.
Collapse
Affiliation(s)
- Javier López-Vidal
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Silvia Gómez-Sebastián
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, Madrid, Spain
| | - Maria del Carmen Nuñez
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Diego Martínez-Alonso
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Benoit Dudognon
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Eva Guijarro
- Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Autovia A6 Km 7, Madrid, Spain
| | - José M. Escribano
- Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Autovia A6 Km 7, Madrid, Spain
- * E-mail:
| |
Collapse
|
10
|
Bárcena J, Guerra B, Angulo I, González J, Valcárcel F, Mata CP, Castón JR, Blanco E, Alejo A. Comparative analysis of rabbit hemorrhagic disease virus (RHDV) and new RHDV2 virus antigenicity, using specific virus-like particles. Vet Res 2015; 46:106. [PMID: 26403184 PMCID: PMC4581117 DOI: 10.1186/s13567-015-0245-5] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 08/12/2015] [Indexed: 12/22/2022] Open
Abstract
In 2010 a new Lagovirus related to rabbit haemorrhagic disease virus (RHDV) emerged in France and has since rapidly spread throughout domestic and wild rabbit populations of several European countries. The new virus, termed RHDV2, exhibits distinctive genetic, antigenic and pathogenic features. Notably, RHDV2 kills rabbits previously vaccinated with RHDV vaccines. Here we report for the first time the generation and characterization of RHDV2-specific virus-like particles (VLPs). Our results further confirmed the differential antigenic properties exhibited by RHDV and RHDV2, highlighting the need of using RHDV2-specific diagnostic assays to monitor the spread of this new virus.
Collapse
Affiliation(s)
- Juan Bárcena
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, Madrid, Spain.
| | - Beatriz Guerra
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, Madrid, Spain.
| | - Iván Angulo
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, Madrid, Spain.
| | - Julia González
- Villamagna SA, Finca "La Garganta", Villanueva de Córdoba, Córdoba, Spain.
| | - Félix Valcárcel
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, Madrid, Spain.
| | - Carlos P Mata
- Department of Structure of Macromolecules, Centro Nacional de Biotecnología/CSIC, Cantoblanco, Madrid, Spain.
| | - José R Castón
- Department of Structure of Macromolecules, Centro Nacional de Biotecnología/CSIC, Cantoblanco, Madrid, Spain.
| | - Esther Blanco
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, Madrid, Spain.
| | - Alí Alejo
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, Madrid, Spain.
| |
Collapse
|
11
|
Crisci E, Fraile L, Novellas R, Espada Y, Cabezón R, Martínez J, Cordoba L, Bárcena J, Benitez-Ribas D, Montoya M. In vivo tracking and immunological properties of pulsed porcine monocyte-derived dendritic cells. Mol Immunol 2014; 63:343-54. [PMID: 25282042 DOI: 10.1016/j.molimm.2014.08.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2014] [Revised: 08/27/2014] [Accepted: 08/28/2014] [Indexed: 02/06/2023]
Abstract
Cellular therapies using immune cells and in particular dendritic cells (DCs) are being increasingly applied in clinical trials and vaccines. Their success partially depends on accurate delivery of cells to target organs or migration to lymph nodes. Delivery and subsequent migration of cells to regional lymph nodes is essential for effective stimulation of the immune system. Thus, the design of an optimal DC therapy would be improved by optimizing technologies for monitoring DC trafficking. Magnetic resonance imaging (MRI) represents a powerful tool for non-invasive imaging of DC migration in vivo. Domestic pigs share similarities with humans and represent an excellent animal model for immunological studies. The aim of this study was to investigate the possibility using pigs as models for DC tracking in vivo. Porcine monocyte derived DC (MoDC) culture with superparamagnetic iron oxide (SPIO) particles was standardized on the basis of SPIO concentration and culture viability. Phenotype, cytokine production and mixed lymphocyte reaction assay confirmed that porcine SPIO-MoDC culture were similar to mock MoDCs and fully functional in vivo. Alike, similar patterns were obtained in human MoDCs. After subcutaneous inoculation in pigs, porcine SPIO-MoDC migration to regional lymph nodes was detected by MRI and confirmed by Perls staining of draining lymph nodes. Moreover, after one dose of virus-like particles-pulsed MoDCs specific local and systemic responses were confirmed using ELISPOT IFN-γ in pigs. In summary, the results in this work showed that after one single subcutaneous dose of pulsed MoDCs, pigs were able to elicit specific local and systemic immune responses. Additionally, the dynamic imaging of MRI-based DC tracking was shown using SPIO particles. This proof-of-principle study shows the potential of using pigs as a suitable animal model to test DC trafficking with the aim of improving cellular therapies.
Collapse
Affiliation(s)
- Elisa Crisci
- Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain
| | | | - Rosa Novellas
- Fundació Hospital Clínic Veterinari, Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès Barcelona, Spain
| | - Yvonne Espada
- Fundació Hospital Clínic Veterinari, Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès Barcelona, Spain
| | - Raquel Cabezón
- Fundació Clínic per la Recerca Biomèdica, Centre Esther Koplowitz, Barcelona, Spain
| | - Jorge Martínez
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona, Spain
| | - Lorena Cordoba
- Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (INIA-CISA), Valdeolmos, 28130 Madrid, Spain
| | - Daniel Benitez-Ribas
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) and Centre Esther Koplowitz, Barcelona, Spain
| | - María Montoya
- Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain; Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Barcelona, Spain.
| |
Collapse
|
12
|
Abstract
Virus-like particles (VLPs) are formed by viral structural proteins that, when overexpressed, spontaneously self-assemble into particles that are antigenically indistinguishable from infectious virus or subviral particles. VLPs are appealing as vaccine candidates because their inherent properties (i.e., virus-sized, multimeric antigens, highly organised and repetitive structure, not infectious) are suitable for the induction of safe and efficient humoral and cellular immune responses. VLP-based vaccines have already been licensed for human and veterinary use, and many more vaccine candidates are currently in late stages of evaluation. Moreover, the development of VLPs as platforms for foreign antigen display has further broadened their potential applicability both as prophylactic and therapeutic vaccines. This chapter provides an overview on the design and use of VLPs for the development of new generation vaccines.
Collapse
Affiliation(s)
- Juan Bárcena
- Centro de Investigación en Sanidad Animal (INIA), Valdeolmos, 28130, Madrid, Spain,
| | | |
Collapse
|
13
|
Abstract
Vaccination is considered one of the most effective ways to control pathogens and prevent diseases in humans as well as in the veterinary field. Traditional vaccines against animal viral diseases are based on inactivated or attenuated viruses, but new subunit vaccines are gaining attention from researchers in animal vaccinology. Among these, virus-like particles (VLPs) represent one of the most appealing approaches opening up interesting frontiers in animal vaccines. VLPs are robust protein scaffolds exhibiting well-defined geometry and uniformity that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines; nevertheless, only one veterinary VLP-base vaccine is licensed. Here, we review and examine in detail the current status of VLPs as a vaccine strategy in the veterinary field, and discuss the potential advantages and challenges of this technology.
Collapse
Affiliation(s)
- Elisa Crisci
- Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain
| | - María Montoya
- Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.,Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Barcelona, Spain
| |
Collapse
|
14
|
Crisci E, Bárcena J, Montoya M. Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol 2012; 148:211-25. [PMID: 22705417 PMCID: PMC7112581 DOI: 10.1016/j.vetimm.2012.04.026] [Citation(s) in RCA: 102] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2011] [Revised: 04/25/2012] [Accepted: 04/26/2012] [Indexed: 12/12/2022]
Abstract
Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches. VLPs are robust protein cages in the nanometer range that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as a vaccine technology in the veterinary field, and discuss the potential advantages and challenges of this technology.
Collapse
Affiliation(s)
- Elisa Crisci
- Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
| | | | | |
Collapse
|
15
|
Cubillos C, de la Torre BG, Bárcena J, Andreu D, Sobrino F, Blanco E. Inclusion of a specific T cell epitope increases the protection conferred against foot-and-mouth disease virus in pigs by a linear peptide containing an immunodominant B cell site. Virol J 2012; 9:66. [PMID: 22416886 PMCID: PMC3313860 DOI: 10.1186/1743-422x-9-66] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2011] [Accepted: 03/14/2012] [Indexed: 11/23/2022] Open
Abstract
Background Foot-and-mouth disease virus (FMDV) causes an economically important and highly contagious disease of cloven-hoofed animals. FMD control in endemic regions is implemented using chemically inactivated whole-virus vaccines. Currently, efforts are directed to the development of safe and marked vaccines. We have previously reported solid protection against FMDV conferred by branched structures (dendrimeric peptides) harbouring virus-specific B and T-cell epitopes. In order to gain insights into the factors determining a protective immune response against FMDV, in this report we sought to dissect the immunogenicity conferred by different peptide-based immunogens. Thus, we have assessed the immune response and protection elicited in pigs by linear peptides harbouring the same FMDV B-cell or B and T-cell epitopes (B and TB peptides, respectively). Results Pigs were twice immunized with either the B-cell epitope (site A) peptide or with TB, a peptide where the B-cell epitope was in tandem with the T-cell epitope [3A (21-35)]. Both, B and TB peptides were able to induce specific humoral (including neutralizing antibodies) and cellular immune responses against FMDV, but did not afford full protection in pigs. The data obtained showed that the T-cell epitope used is capable to induce efficient T-cell priming that contributes to improve the protection against FMDV. However, the IgA titres and IFNγ release elicited by these linear peptides were lower than those detected previously with the dendrimeric peptides. Conclusions We conclude that the incorporation of a FMDV specific T-cell epitope in the peptide formulation allows a significant reduction in virus excretion and clinical score after challenge. However, the linear TB peptide did not afford full protection in challenged pigs, as that previously reported using the dendrimeric construction indicating that, besides the inclusion of an adecuate T-cell epitope in the formulation, an efficient presentation of the B-cell epitope is crucial to elicit full protection by peptide vaccines.
Collapse
Affiliation(s)
- Carolina Cubillos
- Centro de Investigación en Sanidad Animal (CISA-INIA), Carretera de Algete a El Casar, Valdeolmos, 28130 Madrid, Spain
| | | | | | | | | | | |
Collapse
|
16
|
Crisci E, Fraile L, Moreno N, Blanco E, Cabezón R, Costa C, Mussá T, Baratelli M, Martinez-Orellana P, Ganges L, Martínez J, Bárcena J, Montoya M. Chimeric calicivirus-like particles elicit specific immune responses in pigs. Vaccine 2012; 30:2427-39. [PMID: 22306796 PMCID: PMC7115503 DOI: 10.1016/j.vaccine.2012.01.069] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2011] [Revised: 01/20/2012] [Accepted: 01/22/2012] [Indexed: 11/29/2022]
Abstract
Virus-like particles (VLPs) have received considerable attention due to their potential application in veterinary vaccines and, in particular, VLPs from rabbit haemorrhagic disease virus (RHDV) have successfully shown to be good platforms for inducing immune responses against an inserted foreign epitope in mice. The aim of this study was to assess the immunogenicity of chimeric RHDV-VLPs as vaccine vectors in pigs. For this purpose, we have generated chimeric VLPs containing a well-known T epitope of 3A protein of foot-and-mouth disease virus (FMDV). Firstly, RHDV-VLPs were able to activate immature porcine bone marrow-derived dendritic cells (poBMDCs) in vitro. Secondly, pigs were inoculated twice in a two-week interval with chimeric RHDV-VLPs at different doses intranasally or intramuscularly. One intramuscularly treated group was also inoculated with adjuvant Montanide™ ISA 206 at the same time. Specific IgG and IgA antibodies against RHDV-VLPs were induced and such levels were higher in the adjuvanted group compared with other groups. Interestingly, anti-RHDV-VLP IgA responses were higher in groups inoculated intramuscularly than those that received the VLPs intranasally. Two weeks after the last immunisation, specific IFN-γ-secreting cells against 3A epitope and against RHDV-VLPs were detected in PBMCs by ELISPOT. The adjuvanted group exhibited the highest IFN-γ-secreting cell numbers and lymphoproliferative specific T cell responses against 3A epitope and RHDV-VLP. This is the first immunological report on the potential use of chimeric RHDV-VLPs as antigen carriers in pigs.
Collapse
Affiliation(s)
- E Crisci
- Centre de Recerca en Sanitat Animal, UAB-IRTA, Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Castón JR, Luque D, González JM, Gómez-Blanco J, Chichón J, Mena I, Angulo I, Bárcena J. Control of the capacity for structural polymorphism of a T=3 capsid protein. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311094311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
18
|
Brun A, Bárcena J, Blanco E, Borrego B, Dory D, Escribano JM, Le Gall-Reculé G, Ortego J, Dixon LK. Current strategies for subunit and genetic viral veterinary vaccine development. Virus Res 2011; 157:1-12. [PMID: 21316403 DOI: 10.1016/j.virusres.2011.02.006] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2010] [Revised: 02/03/2011] [Accepted: 02/04/2011] [Indexed: 12/24/2022]
Abstract
Developing vaccines for livestock provides researchers with the opportunity to perform efficacy testing in the natural hosts. This enables the evaluation of different strategies, including definition of effective antigens or antigen combinations, and improvement in delivery systems for target antigens so that protective immune responses can be modulated or potentiated. An impressive amount of knowledge has been generated in recent years on vaccine strategies and consequently a wide variety of antigen delivery systems is now available for vaccine research. This paper reviews several antigen production and delivery strategies other than those based on the use of live viral vectors. Genetic and protein subunit vaccines as well as alternative production systems are considered in this review.
Collapse
Affiliation(s)
- Alejandro Brun
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, 28130 Madrid, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Angulo E, Bárcena J. Towards a unique and transmissible vaccine against myxomatosis and rabbit haemorrhagic disease for rabbit populations. Wildl Res 2007. [DOI: 10.1071/wr06160] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Currently available vaccines against myxomatosis and rabbit hemorrhagic disease virus (RHDV) are not suited to immunise wild rabbit populations, as vaccines need to be delivered individually by conventional veterinary practices. As an alternative approach, research in Spain has focused on the development of a transmissible vaccine. A recombinant virus has been constructed based on a naturally attenuated myxoma virus (MV) field strain, expressing the RHDV capsid protein (VP60). Following inoculation of rabbits, the recombinant virus (MV-VP60) induced specific antibody responses against MV and RHDV, conferring protection against lethal challenges with both viruses. Furthermore, the recombinant MV-VP60 virus showed a limited horizontal transmission capacity, either by direct contact or in a flea-mediated process, promoting immunisation of contact uninoculated animals. Efficacy and safety of the vaccine have been extensively evaluated under laboratory conditions and in a limited field trial. The development of the transmissible vaccine strategy and the steps being taken to obtain the marketing authorisation for the vaccine in the European Union are presented in this review.
Collapse
|
20
|
Bárcena J, Verdaguer N, Roca R, Morales M, Angulo I, Risco C, Carrascosa JL, Torres JM, Castón JR. The coat protein of Rabbit hemorrhagic disease virus contains a molecular switch at the N-terminal region facing the inner surface of the capsid. Virology 2004; 322:118-34. [PMID: 15063122 DOI: 10.1016/j.virol.2004.01.021] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2003] [Revised: 01/16/2004] [Accepted: 01/19/2004] [Indexed: 11/22/2022]
Abstract
To function adequately, many if not all proteins involved in macromolecular assemblies show conformational polymorphism as an intrinsic feature. This general strategy has been described for many essential cellular processes. Here we describe this structural polymorphism in a viral protein, the coat protein of Rabbit hemorrhagic disease virus (RHDV), which is required during virus capsid assembly. By combining genetic, structure modeling, and cryo-electron microscopy and image processing analysis, we have established the mechanism that allows RHDV coat protein to switch among quasi-equivalent conformational states to achieve the appropriate curvature for the formation of a closed shell. The RHDV capsid structure is based on a T = 3 lattice, containing 180 copies of identical subunits, similar to those of other caliciviruses. The quasi-equivalent interactions between the coat proteins are achieved by the N-terminal region of a subset of subunits, which faces the inner surface of the capsid shell. Mutant coat protein lacking this N-terminal sequence assembles into T = 1 capsids. Our results suggest that the polymorphism of the RHDV T = 3 capsid might bear resemblance to that of plant virus T = 3 capsids.
Collapse
Affiliation(s)
- Juan Bárcena
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, 28130, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Morales M, Bárcena J, Ramírez MA, Boga JA, Parra F, Torres JM. Synthesis in vitro of rabbit hemorrhagic disease virus subgenomic RNA by internal initiation on (-)sense genomic RNA: mapping of a subgenomic promoter. J Biol Chem 2004; 279:17013-8. [PMID: 14744857 DOI: 10.1074/jbc.m313674200] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Rabbit hemorrhagic disease virus (RHDV), a positive-strand RNA virus, is the type species of the Lagovirus within the Caliciviridae. In addition to the genomic RNA of 7.4 kb, a subgenomic mRNA (sgRNA) of 2.2 kb, which is identical in sequence to the 3' one-third of the genomic RNA, is also synthesized in RHDV-infected cells. Numerous RNA viruses make sgRNA for expression of their 3'-proximal genes. A relevant mechanism for viral gene expression is the regulation of sgRNA synthesis by specific promoter elements. In this study, we have investigated in vitro the sgRNA synthesis mechanism using recombinant RHDV RNA-dependent RNA polymerase produced in baculovirus-infected insect cells and synthetic RHDV (-)RNAs of different lengths containing regions located upstream of the subgenomic start site. We report evidences supporting that the sgRNA of RHDV is synthesized in vitro by internal initiation (subgenomic promoter) on (-)RNA templates of genomic length. The deletion mapping of the subgenomic promoter starting from minus-strand genomic length RNA showed that a sequence of 50 nucleotides upstream of the sgRNA start site (+1) is sufficient for full subgenomic promoter activity in an in vitro assay using recombinant RHDV RNA-dependent RNA polymerase. This study reports the first description of a subgenomic promoter in a member of the Caliciviridae.
Collapse
Affiliation(s)
- Mónica Morales
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, 28130 Madrid, Spain
| | | | | | | | | | | |
Collapse
|
22
|
Torres JM, Sánchez C, Ramírez MA, Morales M, Bárcena J, Ferrer J, Espuña E, Pagès-Manté A, Sánchez-Vizcaíno JM. First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease. Vaccine 2001; 19:4536-43. [PMID: 11483281 DOI: 10.1016/s0264-410x(01)00184-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
As a novel approach for immunisation of wild rabbits, we have recently developed a transmissible vaccine against myxomatosis and rabbit hemorrhagic disease (RHD) based on a recombinant myxoma virus (MV) expressing the RHDV capsid protein [J. Virol. 74 (2000) 1114]. The efficacy and safety of the vaccine have been extensively evaluated under laboratory conditions. In this study, we report the first limited field trial of the candidate vaccine that was undertaken in an island of 34 Has containing a population of around 300 rabbits. Following administration by the subcutaneous route to 76 rabbits, the vaccine induced specific antibody responses against both myxomatosis and RHDV in all the inoculated rabbits. Furthermore, the recombinant virus exhibited a limited horizontal transmission capacity, promoting seroconversion of around 50% of the uninoculated rabbit population. No evidence of undesirable effects due to the recombinant virus field release was detected.
Collapse
Affiliation(s)
- J M Torres
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, 28130, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Torres JM, Ramírez MA, Morales M, Bárcena J, Vázquez B, Espuña E, Pagès-Manté A, Sánchez-Vizcaíno JM. Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease. Vaccine 2000; 19:174-82. [PMID: 10930670 PMCID: PMC7125741 DOI: 10.1016/s0264-410x(00)00183-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit haemorragic disease using a recombinant myxoma virus. J. Virol. 2000;74:1114-23]. Administration of the recombinant virus protects rabbits against lethal RHDV and MV challenges. Furthermore, the recombinant virus is capable of horizontal spreading promoting protection of contact animals, thus providing the opportunity to immunize wild rabbit populations. However, potential risks must be extensively evaluated before considering its field use. In this study several safety issues concerning the proposed vaccine have been evaluated under laboratory conditions. Results indicated that vaccine administration is safe even at a 100-fold overdose. No undesirable effects were detected upon administration to immunosuppressed or pregnant rabbits. The recombinant virus maintained its attenuated phenotype after 10 passages in vivo.
Collapse
Affiliation(s)
- J M Torres
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdemos, Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Bárcena J, Pagès-Manté A, March R, Morales M, Ramírez MA, Sánchez-Vizcaíno JM, Torres JM. Isolation of an attenuated myxoma virus field strain that can confer protection against myxomatosis on contacts of vaccinates. Arch Virol 2000; 145:759-71. [PMID: 10893154 DOI: 10.1007/s007050050669] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Twenty MV strains obtained from a survey of field strains currently circulating throughout Spain were analyzed for their virulence and horizontal spreading among rabbits by contact transmission. A virus strain with suitable characteristics to be used as a potential vaccine against myxomatosis in wild rabbit populations was selected. Following inoculation, the selected MV strain elicited high levels of MV specific antibodies and induced protection of rabbits against a virulent MV challenge. Furthermore, the attenuated MV was transmitted to 9 out of 16 uninoculated rabbits by contact, inducing protection against myxomatosis.
Collapse
Affiliation(s)
- J Bárcena
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
25
|
Bárcena J, Lorenzo MM, Sánchez-Puig JM, Blasco R. Sequence and analysis of a swinepox virus homologue of the vaccinia virus major envelope protein P37 (F13L). J Gen Virol 2000; 81:1073-85. [PMID: 10725435 DOI: 10.1099/0022-1317-81-4-1073] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
P37 (F13L gene product), the most abundant protein in the envelope of the extracellular virus form of the prototype poxvirus, vaccinia virus (VV), is a crucial player in the process leading to acquisition of the envelope, virus egress and transmission. We have cloned and sequenced a swinepox virus (SPV) gene homologous to VV F13L. The SPV gene product, termed P42, was 54% identical to P37, the VV F13L gene product, and, among the poxviruses, was most similar (73% identity) to the myxoma virus homologue. The SPV P42 gene contained late transcription signals and was expressed only at late times during infection. The protein was palmitylated, and showed an intracellular distribution similar to that of VV P37, both by immunofluorescence and by subcellular fractionation. As with VV P37, SPV P42 was incorporated in extracellular enveloped SPV particles, but was absent from the intracellular mature virus form. To check the ability of SPV P42 to function in the context of VV infection, we inserted the SPV gene into a VV deficient in P37, which is severely blocked in virus envelopment and cell-to-cell transmission. Despite correct expression of SPV P42, the resulting recombinant VV showed no rescue of extracellular virus formation or cell-to-cell virus spread. The lack of function of SPV P42 in the VV genetic background suggests that specific interactions between SPV P42 or VV P37 and other viral proteins is required to drive the envelopment process.
Collapse
Affiliation(s)
- J Bárcena
- Centro de Investigación en Sanidad Animal-INIA, Valdeolmos, E-28130 Madrid, Spain
| | | | | | | |
Collapse
|
26
|
Bárcena J, Morales M, Vázquez B, Boga JA, Parra F, Lucientes J, Pagès-Manté A, Sánchez-Vizcaíno JM, Blasco R, Torres JM. Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus. J Virol 2000; 74:1114-23. [PMID: 10627521 PMCID: PMC111445 DOI: 10.1128/jvi.74.3.1114-1123.2000] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/1999] [Accepted: 11/01/1999] [Indexed: 11/20/2022] Open
Abstract
We have developed a new strategy for immunization of wild rabbit populations against myxomatosis and rabbit hemorrhagic disease (RHD) that uses recombinant viruses based on a naturally attenuated field strain of myxoma virus (MV). The recombinant viruses expressed the RHDV major capsid protein (VP60) including a linear epitope tag from the transmissible gastroenteritis virus (TGEV) nucleoprotein. Following inoculation, the recombinant viruses induced specific antibody responses against MV, RHDV, and the TGEV tag. Immunization of wild rabbits by the subcutaneous and oral routes conferred protection against virulent RHDV and MV challenges. The recombinant viruses showed a limited horizontal transmission capacity, either by direct contact or in a flea-mediated process, promoting immunization of contact uninoculated animals.
Collapse
Affiliation(s)
- J Bárcena
- Centro de Investigación en Sanidad Animal, Valdeolmos, 28130 Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Bárcena J, Blasco R. Recombinant swinepox virus expressing beta-galactosidase: investigation of viral host range and gene expression levels in cell culture. Virology 1998; 243:396-405. [PMID: 9568038 DOI: 10.1006/viro.1998.9053] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Swinepox virus (SPV) has been proposed as a potential vector for generating recombinant vaccines for swine. However, little is known about important aspects of SPV biology, such as the functionality of SPV promoters or the host range of SPV. Using a transient expression assay, well-characterized vaccinia virus promoters were shown to be active in cells infected with SPV. A recombinant SPV expressing beta-galactosidase (beta-gal) was constructed and characterized. The E. coli LacZ gene was placed under the control of a strong vaccinia synthetic early/late promoter and was inserted by homologous recombination in a noncoding region of the SPV genome. The recombinant SPV expressing beta-gal was used to characterize the host range of the virus by measuring protein expression and virus production in different cell lines. In general, SPV expressed more protein and grew more efficiently than vaccinia virus in porcine cell lines. Surprisingly, the recombinant SPV was able to infect and replicate in several cell lines of nonswine origin. The virus directed regulated early and late gene expression of beta-gal in those cells and formed blue plaques in cell monolayers in the presence of X-gal. Upon infection with the recombinant SPV, there was a significant level of viral replication, and the virus can be serially passaged in some nonswine cell lines. The data presented suggest that despite the strict host tropism of SPV, the virus exhibits a relatively broad host range in cell culture.
Collapse
Affiliation(s)
- J Bárcena
- Centro de Investigación en Sanidad Animal-I.N.I.A., Valdeolmos, Madrid, Spain
| | | |
Collapse
|
28
|
Jambrina E, Bárcena J, Uez O, Portela A. The three subunits of the polymerase and the nucleoprotein of influenza B virus are the minimum set of viral proteins required for expression of a model RNA template. Virology 1997; 235:209-17. [PMID: 9281500 DOI: 10.1006/viro.1997.8682] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The genes encoding the nucleoprotein, PB1, PB2, and PA proteins of the influenza virus strain B/Panamá/45/90 have been cloned under control of the T7 RNA polymerase promoter of plasmid pGEM-3. Transfection of the recombinant plasmids obtained into mammalian cells, which had been infected with a vaccinia virus encoding the T7 RNA polymerase, resulted in expression of the expected influenza B virus polypeptides. Moreover, it is shown that coexpression of the four recombinant core proteins in COS-1 cells reconstituted a functional polymerase capable of expressing a synthetic influenza B virus-like CAT RNA. By using the influenza B virus recombinant plasmids and a set of pGEM-derived plasmids encoding the homologous core proteins of the influenza A virus A/Victoria/3/75 (I. Mena et al. (1994). J. Gen. Virol. 75, 2109-2114), the capabilities of homo- and heterotypic mixtures of the four core proteins to express synthetic type A and B CAT RNAs were analyzed. Both the influenza A and B virus polymerases were active in expressing, albeit with reduced efficiencies, the heterotypic model CAT RNAs. However, none of all possible heterotypic mixtures of the core proteins reconstituted a functional polymerase. In order to fully characterize the recombinant plasmids obtained, the nucleotide sequences of the cloned genes were determined and compared to sequences of other type B virus isolates. The results obtained from these latter analyses are discussed in terms of the conservation and evolution of the influenza B virus core genes.
Collapse
Affiliation(s)
- E Jambrina
- Instituto de Salud Carlos III, Centro Nacional de Biología Fundamental, Majadahonda 28220, Madrid, Spain
| | | | | | | |
Collapse
|
29
|
Varona L, Sagasta A, Bárcena J, Zarranz JJ. Neurological manifestations following treatment of Langerhans cell histiocytosis. J Neurol 1997; 244:58-60. [PMID: 9007748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
30
|
Antigüedad A, Bárcena J, Pérez Bas M, Aldape J, Hurtado P, Zarranz JJ. [The practice of neurology by regional specialists in Vizcaya (Spain)]. Neurologia 1995; 10:324-9. [PMID: 8554782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
We describe the practice of 3 regional specialists in neurology in 1993 and 1994 at Hospital de Cruces in Vizcaya. Each neurologist alternately spent 1 day working in the hospital ward and another day working in an external clinic in the region, thus allowing clinic patients to be seen consistently by the same neurologist, while responsibility for inpatients could be shared by 2 physicians. All clinic patients in the region and the majority of hospital patients were covered by these specialists. A yearly average of 683.05 new patients were seen; 177.72 (26.01%) as inpatients, 82 (12%) at the hospital-based outpatient clinic and 423.33 (61.98%) at other clinics in the region. The wait time for new patients in the regional clinics was 119.71 days; 21.97% of these patients were classified as having no neurological disease (with diagnoses of syncope and peripheral vertigo included in this group), 25.74% had headache and 40.12% had cerebrovascular, neuromuscular, degenerative disease or epilepsy. Hospitalized patients released with diagnoses of non-neurological disease or cephalea represented 12.91% of the total; 50.6% of hospital patients had cerebrovascular disease.
Collapse
Affiliation(s)
- A Antigüedad
- Servicio de Neurología, Hospital de Cruces, Vizcaya
| | | | | | | | | | | |
Collapse
|
31
|
Ochoa M, Bárcena J, de la Luna S, Melero JA, Douglas AR, Nieto A, Ortín J, Skehel JJ, Portela A. Epitope mapping of cross-reactive monoclonal antibodies specific for the influenza A virus PA and PB2 polypeptides. Virus Res 1995; 37:305-15. [PMID: 8533465 DOI: 10.1016/0168-1702(95)00039-s] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Characterization of the epitopes recognized by 21 monoclonal antibodies (MAbs) specific for the influenza A virus PA (13 MAbs) and PB2 (8 MAbs) polypeptides (Bárcena et al. (1994) J. Virol. 68, 6900-6909) raised against denatured polypeptides produced in E. coli is described. MAbs were characterized by: (1) competitive binding ELISAs; (2) mapping of the protein regions that specify their binding sites; and (3) analyses of their ability to recognize the corresponding viral protein in a number of viral isolates. Five and three non-overlapping antigenic areas were defined by the anti-PA and anti-PB2 MAbs, respectively. Five of the anti-PA MAbs recognized antigenic determinants located within the amino-terminal 157 amino acids of the PA protein, and 6 others reacted strongly with a PA fragment comprising the first 236 amino acids. All 8 anti-PB2 antibodies reacted strongly with a polypeptide fragment containing amino acids 1-113 of the PB2 protein. Analyses of the reactivities of 4 anti-P antibodies with 23 influenza A virus reference strains isolated over a period of 61 years and recovered from humans, pigs, birds and horses, showed that the epitopes were conserved among all viral isolates. The application of these antibodies as research and diagnostic tools is discussed.
Collapse
Affiliation(s)
- M Ochoa
- Instituto de Salud Carlos III, Centro Nacional de Biología Celular y Retrovirus, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Zarranz JJ, Antigüedad AR, Bárcena J. [Psychotic crisis symptomatic of an outbreak of multiple sclerosis]. Neurologia 1995; 10:205-8. [PMID: 7619539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Mental disorders (especially depression and dementia) are highly prevalent among multiple sclerosis (MS) patients. Schizophrenic-type psychosis has been reported only rarely most often in advanced cases and its possible pathophysiological and even causal relation to the demyelinating disease is disputed. We describe a woman with MS who experienced 2 episodes of acute psychosis after having had only one prior episode of focal neurological dysfunction. The coincidence of psychiatric symptoms and the appearance of new white matter lesions in both hemispheres was confirmed by CT and MRI during the second episode. We suggest that in this patient the psychotic symptoms do not depend on the strategic anatomical location of plates, but rather on the effect of nonspecific lesions in a patient previously predisposed to psychiatric disorder.
Collapse
Affiliation(s)
- J J Zarranz
- Hospital de Cruces, Departamento de Neurociencias, Universidad del País Vasco
| | | | | |
Collapse
|
33
|
Bárcena J, Ochoa M, de la Luna S, Melero JA, Nieto A, Ortín J, Portela A. Monoclonal antibodies against influenza virus PB2 and NP polypeptides interfere with the initiation step of viral mRNA synthesis in vitro. J Virol 1994; 68:6900-9. [PMID: 7933070 PMCID: PMC237125 DOI: 10.1128/jvi.68.11.6900-6909.1994] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Two panels of monoclonal antibodies (MAbs) specific for the influenza A virus PA and PB2 polypeptides have been obtained from mice immunized with denatured proteins produced in Escherichia coli. All MAbs (13 specific for the PA polypeptide and 8 specific for the PB2 protein) reacted to the corresponding influenza virus protein in Western blotting (immunoblotting), immunoprecipitation, and immunofluorescence assays. To gain information about the roles of the nucleoprotein (NP) and PB2 and PA proteins during viral mRNA synthesis, the 21 anti-P antibodies and 3 anti-NP antibodies (J. A. López, M. Guillen, A. Sánchez-Fauquier, and J. A. Melero, J. Virol. Methods 13:255-264, 1986) were purified and tested for their ability to inhibit the transcriptase activity associated with viral cores purified from virions. Four of the antibodies (one anti-PB2 and the three anti-NP MAbs) inhibited transcription by more than 50% compared with unrelated control antibodies. The inhibitory effect was not due to a nonspecific effect of the antibody preparations, because these MAbs did not inhibit transcription when tested on influenza B virus nucleocapsids, which are not recognized by the antibodies. To determine whether the antibodies were acting on an early transcription step, transcription reactions were carried out in the presence of globin mRNA (a mixture of alpha- and beta-globin chains) and only one labeled nucleoside triphosphate (either GTP or CTP). The results obtained showed that MAbs to the PB2 and NP polypeptides interfered with the initiation step of mRNA-primed transcription. The implications of these results regarding initiation of viral mRNA synthesis are discussed.
Collapse
Affiliation(s)
- J Bárcena
- Centro Nacional de Microbiología Virología e Inmunología Sanitarias, Instituto de Salud Carlos III, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
34
|
Nieto A, de la Luna S, Bárcena J, Portela A, Ortín J. Complex structure of the nuclear translocation signal of influenza virus polymerase PA subunit. J Gen Virol 1994; 75 ( Pt 1):29-36. [PMID: 8113737 DOI: 10.1099/0022-1317-75-1-29] [Citation(s) in RCA: 86] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The protein regions involved in the nuclear translocation of the influenza virus PA polymerase subunit have been identified by deletion analysis of the protein expressed from a recombinant simian virus 40. Two regions seem to play a role in the process: region I (amino acids 124 to 139) and region II (amino acids 186 to 247). A nucleoplasmin-like nuclear translocation signal (NLS) has been identified in region I and an additional NLS appears to be present in region II, although no consensus targeting sequence can be detected. Alteration in any of the regions identified by short deletions completely prevented nuclear transport, whereas elimination of the regions I or II by large amino- or carboxy-terminal deletions did not prevent nuclear targeting of the truncated protein. In addition, a point mutation at position 154 completely eliminated nuclear transport. A beta-galactosidase fusion protein containing the 280 amino acid terminal region of the PA protein was partially transported to the nucleus and mutant PA proteins with a cytoplasmic phenotype could not be rescued by superinfection with influenza virus. These results suggest that the PA protein contains a functional nuclear targeting region which is required in influenza virus infection, with two independent NLSs, one in region I and the other in region II.
Collapse
Affiliation(s)
- A Nieto
- Centro Nacional de Biotecnología (CSIC), Universidad Autónoma, Madrid, Spain
| | | | | | | | | |
Collapse
|
35
|
Abstract
The subcellular distribution of influenza polymerase PA subunit has been studied using a SV40-recombinant virus (SVPA76), which allows the expression and accumulation of this protein in COS-1 cells. In contrast to the complete nuclear localization observed for the PA subunit several hours after influenza virus infection, when COS-1 cells were infected with the SVPA76 recombinant, the PA protein accumulated either in the nucleus, in the cytoplasm or was distributed throughout the cell. When cells were infected with the SVPA76 recombinant and superinfected with influenza virus, a clear increase in the proportion of cells showing nuclear localization of the PA protein was observed, suggesting that some trans-factor may be required to allow complete nuclear accumulation of the protein. Double infections using SVPA76 recombinant and either SVPB1 or SVNS recombinant viruses showed a complete correlation between expression of polymerase PB1 subunit or NS1 protein and nuclear localization of polymerase PA subunit. However, no such correlation was observed in the double infections of SVPA76 and SVNP recombinants. These results suggest that polymerase PB1 subunit and the non-structural proteins could be involved in the nuclear targeting or nuclear retention of influenza polymerase PA protein.
Collapse
Affiliation(s)
- A Nieto
- Centro Nacional de Biotecnología (CSIC), Universidad Autónoma, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
36
|
Guarro J, Gaztelurrutia L, Marín J, Bárcena J. [Scedosporium inflatum, a new pathogenic fungus. Report of 2 cases with a fatal outcome]. Enferm Infecc Microbiol Clin 1991; 9:557-60. [PMID: 1822709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Scedosporium inflatum is a newly described human pathogen, their infections primarily involved musculoskeletal tissues. We report 2 fatal cases with disseminated S. inflatum infections in Spanish patients. The fungus was isolated from blood in both cases. Amphotericin B treatment was ineffective. In vitro susceptibility testing of one isolate against 7 antifungal agents is done. These cases illustrate the need to remain vigilant for this new emerging pathogen.
Collapse
Affiliation(s)
- J Guarro
- Unidad de Microbiología, Facultad de Medicina, Universidad de Barcelona, Reus, Tarragona
| | | | | | | |
Collapse
|
37
|
Elías J, Bárcena J. [Botryoid sarcoma of the bladder (racemose rhabdomyosarcoma)]. Rev Invest Clin 1966; 18:67-74. [PMID: 5947178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|